Prof. PeptideProf. Peptide

Sermorelin + Ipamorelin

Growth HormoneResearch-GradeCombination Blend

Last reviewed: September 20, 2026

Quick Facts

What it is
A combination of Sermorelin (a GHRH 1-29 analog) and Ipamorelin (a selective ghrelin / GHS-R1a agonist) that raise growth hormone through two complementary pituitary pathways — the beginner-friendly GH secretagogue stack with the strongest regulatory footing.
How it's taken
Subcutaneous injection, both components pre-bed on an empty stomach
Half-life
Sermorelin ~10–20 min; Ipamorelin ~2 hours
Typical research dose
Sermorelin 100–300 mcg + Ipamorelin 200–300 mcg, pre-bed, in 8–12 week cycles
Research status
Sermorelin was FDA-approved as Geref (later withdrawn) and remains available via compounding pharmacies; Ipamorelin is not approved; the combination is not an approved product — research use only.
On this page
  1. 1.Where to source Sermorelin + Ipamorelin
  2. 2.What is Sermorelin + Ipamorelin?
  3. 3.How does Sermorelin + Ipamorelin work?
  4. 4.What is Sermorelin + Ipamorelin used for?
  5. 5.How long does Sermorelin + Ipamorelin take to work?
  6. 6.How is Sermorelin + Ipamorelin dosed?
  7. 7.How is Sermorelin + Ipamorelin administered?
  8. 8.What does Sermorelin + Ipamorelin stack well with?
  9. 9.What are the side effects of Sermorelin + Ipamorelin?
  10. 10.Does Sermorelin + Ipamorelin interact with other drugs?
  11. 11.How should Sermorelin + Ipamorelin be stored?
  12. 12.What are the limitations of Sermorelin + Ipamorelin research?
  13. 13.Sermorelin + Ipamorelin FAQ
  14. 14.References
  15. 15.Published Studies

Where to source Sermorelin + Ipamorelin

Neither Sermorelin (as research-grade injectable) nor Ipamorelin is FDA-approved for over-the-counter retail sale. Both are sold by specialty research peptide vendors for laboratory use only — typically as separate vials (allowing independent dose titration) or occasionally as a pre-blended combination vial. The vendors highlighted below carry both components and have been vetted for transparent third-party testing and traceable batch documentation.

Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos

See all verified vendors

What is Sermorelin + Ipamorelin?

Sermorelin + Ipamorelin is a 2-component growth hormone secretagogue blend combining Sermorelin (a GHRH 1-29 analog, ~10–20 min half-life) and Ipamorelin (a selective GHS-R1a / ghrelin receptor agonist, ~2 h half-life). Like the GH Stack (CJC-1295 + Ipamorelin), it activates both the GHRH receptor and the ghrelin receptor on pituitary somatotrophs simultaneously, and dual-pathway GHRH+GHRP activation is reported to produce supra-additive growth hormone release in a pulsatile pattern that mirrors physiological GH secretion — a mechanism demonstrated with a different GHRH+GHRP pairing (see Dosing/Mechanism), not tested with Sermorelin and Ipamorelin specifically. What distinguishes this stack is its regulatory footing: Sermorelin was FDA-approved as Geref for pediatric GH deficiency and is available via compounding pharmacies for adult GH deficiency — giving it the strongest safety and regulatory pedigree of the GHRH analogs. Both components are short-acting, preserving physiological pulsatile GH release, and both are WADA S2 prohibited.

This is the recommended starting point on the GH secretagogue stack progression: Sermorelin + Ipamorelin → GH Stack (CJC-1295 no-DAC + Ipamorelin) → CJC-1295 with DAC (once-weekly convenience, non-pulsatile).

New to peptide research? Start with the basics

Reported benefits:

  • Synergistic GH amplification beyond individual compound effects reported for the GHRH+GHRP mechanism class — demonstrated with a different GHRH/GHRP pairing, not Sermorelin and Ipamorelin specifically (see Dosing section)
  • Physiologically pulsatile GH release pattern (both components short-acting — preserves natural feedback regulation)
  • Elevated IGF-1 supporting anabolic, metabolic, and tissue-repair processes
  • No significant cortisol, ACTH, or prolactin elevation (Ipamorelin's selectivity advantage vs older GHRPs)
  • Enhanced slow-wave sleep through GH-mediated nocturnal GH pulse reinforcement
  • Sermorelin has prior FDA approval history as Geref (now listed as discontinued), which provides past clinical exposure data

Common research dose: Sermorelin 100–300 mcg + Ipamorelin 200–300 mcg subcutaneously, pre-bed on an empty stomach, once daily (optional second dose post-workout). These are unverified community-reported figures, not doses from any cited trial: sermorelin's own cited human-trial doses run considerably higher, and no human trial has established a subcutaneous research dose for ipamorelin at all — see the Dosing section for the literature-vs-community breakdown. Community-reported protocols build up from lower doses over weeks 1–2.

Where to buy: Sermorelin and Ipamorelin are sold as separate vials by research peptide vendors; our data does not confirm a pre-blended combination. Neither component is FDA-approved at research-grade doses. See Verified Discount Codes for current options.

How does Sermorelin + Ipamorelin work?

Sermorelin + Ipamorelin combines two peptides that hit the same pituitary gland through different receptor doors. Sermorelin is a GHRH 1-29 analog — it activates the GHRH receptor on pituitary somatotrophs, the same receptor the body's natural growth hormone-releasing hormone uses. Ipamorelin is a selective GHRP, activating the ghrelin / GHS-R1a receptor on the same cells. When both receptors fire simultaneously, the pituitary releases more GH than either signal triggers alone — in a pulsatile pattern that mirrors physiological GH secretion.

  1. Sermorelin — GHRH Pathway Activation [1][4]. Sermorelin (GHRH 1-29) binds the GHRH receptor on anterior pituitary somatotrophs. Activation triggers a Gs-coupled cAMP/PKA cascade that drives GH gene transcription and primes the somatotroph for GH release. A half-life of approximately 10–20 minutes is commonly reported (no published half-life figure for CJC-1295 without DAC was found for comparison), though no published pharmacokinetic study or label has been identified establishing this figure for Sermorelin.
  2. Ipamorelin — GHS-R1a Pathway Activation [1][2]. Ipamorelin selectively activates the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) on the same pituitary somatotrophs. Activation triggers a Gq-coupled phospholipase C / IP3 / calcium / PKC cascade that drives immediate GH release. Ipamorelin's half-life is approximately 2 hours per Gobburu et al. 1999. Its defining feature is selectivity: GH pulse without meaningful cortisol, ACTH, prolactin, FSH, LH, or TSH elevation — distinguishing it from older GHRPs.
  3. Dual-Pathway Synergy [2]. Simultaneous GHRHR activation (cAMP/PKA cascade from Sermorelin) and GHS-R1a activation (calcium/PKC cascade from Ipamorelin) converge at the somatotroph secretory machinery, and the two second-messenger cascades are believed to amplify each other. The supporting trial did not test Sermorelin or Ipamorelin: it combined a hexapeptide GHRP (His-DTrp-Ala-Trp-DPhe-Lys-NH2) with native GHRH(1-44)-NH2, given as IV boluses to 18 men, and reported that submaximal GHRP doses combined with GHRH raised peak serum GH synergistically — the paper's own results are peak GH concentrations, not an AUC ratio, so the often-repeated "2–4× greater GH area under the curve" figure is not a number stated in this abstract. The synergy rationale for pairing a GHRH analog with a GHRP is real, but the specific magnitude and the specific compounds (Sermorelin, Ipamorelin) have not themselves been tested together.
  4. Physiological Pulsatility [3]. The short half-lives of both Sermorelin (~10–20 min) and Ipamorelin (~2 h) produce a discrete GH pulse over 1–2 hours, then return to baseline. This mirrors the body's natural overnight and post-exercise GH pulses, preserving feedback regulation (somatostatin inhibition, IGF-1 feedback) and avoiding the sustained, non-pulsatile GH elevation produced by DAC-conjugated analogs or exogenous HGH. Pulsatile GH is how the pituitary naturally operates.
  5. Downstream IGF-1 Elevation [3]. The amplified pituitary GH output drives elevated hepatic IGF-1 production. IGF-1 carries most of the systemic anabolic and tissue-repair effects — lean mass support, recovery enhancement, joint and connective tissue benefit. Both Sermorelin and CJC-1295 (no-DAC) drive measurable IGF-1 elevation within days of starting a stack protocol.

What is Sermorelin + Ipamorelin used for?

The Sermorelin + Ipamorelin stack is used for the same GH-axis research applications as the GH Stack (CJC-1295 + Ipamorelin), with the additional context that Sermorelin's clinical history provides a closer regulatory analog for safety class. Researchers use it for body composition, recovery, sleep quality, and GH-axis support in the context of age-related GH decline.

  1. Sleep Quality [5]. GHRH administration (including Sermorelin analogs) enhances slow-wave sleep and reinforces the natural nocturnal GH pulse. Pre-bed dosing of Sermorelin + Ipamorelin is studied for sleep-quality improvement. Subjective sleep improvements are sometimes reported as among the first effects, within 1–2 weeks, though no trial or label has been identified establishing this timeframe.
  2. Body Composition [3]. Elevated GH and downstream IGF-1 support lean muscle synthesis, visceral fat metabolism, and overall body composition. The most-cited GH secretagogue use case in the research and biohacking communities. Effects accumulate over 12–24 weeks of active research protocol.
  3. Recovery and Tissue Repair. Elevated GH and IGF-1 support faster recovery from exercise-induced muscle damage through enhanced protein synthesis and cellular repair mechanisms. Often stacked with BPC-157 and TB-500 for combined local + systemic tissue-repair coverage.
  4. GH-Axis Support in Aging [4]. GH axis activity declines significantly with age. Sermorelin was FDA-approved as Geref (both applications now listed as discontinued in Drugs@FDA); compounded sermorelin is not an FDA-approved product. The stack is researched as a means of supporting GH axis function to counteract age-related muscle loss, fat accumulation, and metabolic decline.
  5. Joint and Connective Tissue Support. IGF-1 supports collagen synthesis and connective tissue maintenance. Common research application alongside resistance training and tissue-repair peptide stacks.

How long does Sermorelin + Ipamorelin take to work?

Effects build over weeks. Sleep quality and subjective recovery improvements often appear within the first 1–2 weeks. Subjective joint, connective-tissue, and recovery effects accumulate over 4–8 weeks. Body composition changes take 12–24 weeks to become measurable.

IGF-1 elevation is detectable in serum within days of starting the stack. The Sermorelin + Ipamorelin combination does not produce dramatic short-term changes — it produces gradual, accumulating effects driven by sustained pulsatile elevation of endogenous GH and downstream IGF-1. Standard research cycles run 8–16 weeks active with a similar off-period to avoid pituitary receptor desensitization. Sermorelin's clinical data in GH deficiency shows continued benefit through multi-month treatment with appropriate cycling.

How is Sermorelin + Ipamorelin dosed?

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

Sermorelin + Ipamorelin has not been studied as a combination in any controlled trial. Both components are short-acting, so daily (or twice-daily) dosing is required. Each component's own dosing picture is different: Sermorelin has human trial doses on record, though none match the community figures used here; Ipamorelin has no human trial that established a subcutaneous research-use dose at all. The figures below are a research-community convention, not a validated combined protocol.

What the cited literature administered (per component, not as a combination)

  1. Sermorelin. Human trials of sermorelin and closely related GHRH(1-29) analogs used doses well above the community figures below — a pediatric RCT used 30–60 mcg/kg/day (roughly 1,000–2,000+ mcg/day for an adult-sized body), a placebo-controlled trial in older adults used 10 mcg/kg nightly of a related analog (roughly 700 mcg/night for a 70 kg adult), and an open-label study in elderly men used a flat 2,000 mcg nightly. None of these trials tested sermorelin combined with a GHRP. See the Sermorelin dosing section for the full literature breakdown.
  2. Ipamorelin. No human trial has established a subcutaneous research-use dose for ipamorelin. The cited human trials used intravenous administration — a dose-escalation PK/PD study (roughly 3–100 mcg/kg IV infusion) and a postoperative-ileus Phase 2 trial (0.03 mg/kg IV twice daily). See the Ipamorelin dosing section for details.

Community-reported practice (unverified):

  1. Sermorelin dose. 100–300 mcg subcutaneously per injection — below every cited human trial dose for sermorelin or its close analogs, and not itself drawn from a trial.
  2. Ipamorelin dose. 200–300 mcg subcutaneously per injection (same injection or separate syringe) — a community figure not derived from the cited IV trials, which used a different route and different dose basis.
  3. Frequency. Once daily (pre-bed preferred) or twice daily (pre-bed + post-workout). Pre-bed is the more commonly reported of the two.
  4. Timing. An empty stomach, at least 2 hours after the last meal, is the convention. Elevated insulin and somatostatin blunt the GH response — this is the most important timing constraint.
  5. Titration. Start at the lower end (Sermorelin 100 mcg + Ipamorelin 200 mcg once daily pre-bed) for weeks 1–2, then increase by ~50 mcg each peptide every 1–2 weeks as tolerated toward target doses.
  6. Cycle. 8–12 weeks active, 4-week minimum off-period before re-cycling.

Vial formats and reconstitution math

Common SKUs. Sermorelin comes in 2 mg or 5 mg lyophilized vials; Ipamorelin in 2 mg or 5 mg lyophilized vials. Our data does not confirm a pre-blended Sermorelin + Ipamorelin vial; for one, the vendor's label is the source for component weights, as the ratio is not standardized.

Reconstitution. Bacteriostatic water for injection (BAC water) is reported used. A standard approach: add 2 mL BAC water to a 2 mg Sermorelin vial (1 mg/mL = 1,000 mcg/mL), giving 10 units per 100 mcg dose on a U-100 insulin syringe. Add 2 mL BAC water to a 2 mg Ipamorelin vial (1 mg/mL), giving 20 units per 200 mcg dose. Swirl gently — do not shake — to avoid damaging the peptides.

Separate vials vs pre-blend. Most researchers buy Sermorelin and Ipamorelin as separate vials — this lets them adjust each peptide's dose independently and stagger titration. A pre-blended vial locks the ratio, which is acceptable if that ratio matches the target protocol.

BAC waterConc. (2 mg vial)100 mcg dose150 mcg dose200 mcg dose300 mcg dose
1 mL2 mg/mL (2,000 mcg/mL)5 units7.5 units10 units15 units
2 mL1 mg/mL (1,000 mcg/mL)10 units15 units20 units30 units

Table above applies to a 2 mg single-peptide vial. For different vial sizes or pre-blended vials, use the dosage calculator for ratio-specific math.

Sermorelin + Ipamorelin is not FDA-approved as a research blend. The community dosing figures above are lower than sermorelin's own cited human-trial doses and are not derived from any ipamorelin trial (none has established a subcutaneous research dose) — there are no approved retail dosing standards for the combination, and no clinical dosing precedent for combining the two.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is Sermorelin + Ipamorelin administered?

Both peptides are administered by subcutaneous injection using a small insulin syringe. Pre-bed dosing on an empty stomach is the canonical protocol because it synchronizes with the body's natural overnight GH pulse and the sleep-stage-dependent GH secretion pattern.

  1. Route. Subcutaneous injection. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Pre-bed is the default — 30–60 minutes before sleep on an empty stomach. An optional second dose may be added post-workout if running a 2× daily protocol.
  3. Empty stomach. At least 2 hours after the last meal. Elevated insulin and somatostatin blunt the GH response — this is the most important timing rule for this stack.
  4. Same injection or separate syringes. If using separate vials, both peptides may be drawn into the same insulin syringe for a single injection, or administered as separate injections at the same site-rotation point. The two are not mixed in the same vial for storage.
  5. Site rotation. Reported practice alternates injection sites each dose, staying at least 1 inch from previous injection sites to minimize injection-site reactions.
  6. Reconstitution. Bacteriostatic water for injection (BAC water) is reported used, with a gentle swirl rather than shaking to avoid damaging the lyophilized peptides.
  7. Missed dose. Reported practice resumes on the next scheduled dose. The convention is not to double-dose. For once-daily protocols, a single missed night has minimal impact; consistency over weeks matters more than any single injection.
  8. Cycling. Community-reported, not trial-derived: 8–12 weeks on, 4-week minimum off. Community protocols describe cycling as a way to limit pituitary receptor desensitization (no study testing that was found) and to preserve GH-axis responsiveness over repeated research cycles.

Timing context. Unlike once-weekly GLP-class peptides, Sermorelin and Ipamorelin are both short-acting and timing-sensitive: insulin and somatostatin from a recent meal will blunt the GH response. The table below summarizes the timing variables that most affect the stack's GH output.

AspectReported
Frequency1–2× daily (pre-bed primary; post-workout optional 2nd dose)
Best time of dayPre-bed, 30–60 min before sleep — aligns with natural nocturnal GH pulse and slow-wave sleep onset
FoodEmpty stomach, 2+ hours after last meal (insulin + somatostatin blunt GH response)
Injection site rotationAbdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms, alternated per injection, is the standard subcutaneous-injection pattern
Half-livesSermorelin ~10–20 min; Ipamorelin ~2 h — both short-acting, daily or twice-daily dosing required
Steady-state timelineSleep quality 1–2 weeks; recovery 4–8 weeks; body composition 12–24 weeks

What does Sermorelin + Ipamorelin stack well with?

The stack pairs well with tissue-repair peptides and metabolic compounds — GH-mediated systemic IGF-1 elevation amplifies the local effects of other interventions. Adding another GH secretagogue double-doses the GH axis (MK-677, CJC-1295) or running standalone Sermorelin or Ipamorelin protocols on top of this combination.

  1. Tissue-repair peptides. The most common pairing. BPC-157 + TB-500 (or the Wolverine Stack) for combined local + systemic tissue repair. Elevated IGF-1 amplifies the substrate for local healing peptides.
  2. Stepping up to the GH Stack. Researchers who have established tolerability with Sermorelin + Ipamorelin sometimes step up to GH Stack (CJC-1295 no-DAC + Ipamorelin). No published half-life figure for CJC-1295 no-DAC was found, so a longer action per injection than Sermorelin's ~10–20 min is not established.
  3. Metabolic / weight peptides. GH-axis activation provides lean-mass preservation during caloric restriction — Sermorelin + Ipamorelin is sometimes run alongside fat-loss protocols. Elevated IGF-1 helps offset catabolism.
  4. Tesamorelin substitution. Tesamorelin (FDA-approved GHRH analog for HIV-associated lipodystrophy) is the other regulatory-clean GHRH analog. Researchers targeting visceral fat specifically sometimes substitute Tesamorelin for Sermorelin in this stack format.
  5. Resistance training + adequate protein. Required for GH-mediated anabolic effect. GH and IGF-1 elevation without mechanical loading and protein substrate produces less lean-mass benefit. Recommended: 1.2–1.6 g protein/kg body weight throughout the research cycle.
  6. Conflicts: MK-677. MK-677 (ibutamoren) is another GH secretagogue (ghrelin receptor agonist) — stacking with Ipamorelin doubles the GHS-R1a activation without proportional benefit and increases appetite and potential cortisol side effects.
  7. Conflicts: full-dose standalone CJC-1295 or Sermorelin. Adding a standalone CJC-1295 or Sermorelin protocol on top of this stack doubles the GHRH-pathway activation without independent benefit. Choose one GHRH analog per protocol.

What are the side effects of Sermorelin + Ipamorelin?

Most reported side effects are mild and reflect GH-axis physiology — water retention, transient flushing, injection-site reactions, and early sleep changes. Ipamorelin's selectivity avoids the cortisol and prolactin elevation of older GHRP stacks. Theoretical long-term concerns are insulin resistance and receptor desensitization from sustained GH-axis activation.

Common (most users)

  1. Injection-site reactions. Redness, mild irritation, or transient pinkness at the subcutaneous injection site. The most commonly reported effect; resolved by site rotation.
  2. Transient flushing / head rush. Mild warmth or head rush shortly after injection, most common with the first few doses. Usually resolves within the first 1–2 weeks of continued dosing.
  3. Mild water retention. Reflects normal GH-mediated sodium and fluid effects. Typically mild and resolves on cycle-off.
  4. Transient appetite changes. Generally mild with Ipamorelin (selective) compared to older GHRPs that produced pronounced appetite spikes.

Less common (moderate)

  1. Numbness / tingling in hands. Mild carpal-tunnel-like sensations from GH-related fluid retention. Common with prolonged cycles; resolves on cycle-off.
  2. Mild fasting glucose elevation. GH counter-regulates insulin. Worth monitoring with fasting glucose checks during longer research cycles, particularly in pre-diabetic subjects.
  3. Headache. Typically mild and more common during dose titration. Usually resolves after the first 1–2 weeks at a given dose level.
  4. Vivid dreams or disrupted sleep onset. Reported with pre-bed dosing in some researchers. Usually adapts within the first 1–2 weeks of the cycle.

Serious (rare or theoretical)

  1. Insulin resistance with chronic use. Sustained GH-axis activation can promote insulin resistance. The primary theoretical reason for cycling — 8–12 weeks on, 4-week minimum off.
  2. Pituitary receptor desensitization. Continuous GH-axis stimulation without breaks can downregulate receptor responsiveness. Standard cycling protocols are the mitigation.
  3. Theoretical mitogenic risk. Chronic IGF-1 elevation has a theoretical tumor-stimulation concern from epidemiological associations of high baseline IGF-1 with certain cancer types. No signals have appeared in Sermorelin clinical-use data or GH secretagogue research-community use.
  4. Anti-doping prohibition. Both sermorelin and ipamorelin are named on the 2026 WADA Prohibited List under S2.2.4 (Growth Hormone Releasing Factors) — sermorelin among the GHRH analogues, ipamorelin among the growth hormone secretagogues. The class is prohibited at all times.

Ipamorelin's selectivity profile means the combination avoids the cortisol elevation, prolactin elevation, and excessive appetite that older GHRP stacks produced.

Does Sermorelin + Ipamorelin interact with other drugs?

The stack has limited well-documented systemic drug interactions, but several theoretical concerns apply because GH and IGF-1 affect insulin sensitivity, fluid balance, and tissue growth. Sermorelin's clinical use history means interaction data for the GHRH-pathway component is more developed than for CJC-1295.

  1. Insulin and oral hypoglycemics. GH counter-regulates insulin. Users on insulin, metformin, or other diabetes medications may need dose adjustment. Fasting glucose is worth monitoring during cycles.
  2. Corticosteroids. Chronic corticosteroid use can suppress the GH axis at the pituitary level, potentially blunting the response to the Sermorelin component. No acute safety concern documented.
  3. Other GH-axis compounds. MK-677, HGH itself, IGF-1 LR3, CJC-1295 — overlapping mechanisms increase IGF-1 elevation without proportional benefit and amplify side effects.
  4. Levothyroxine. GH-axis activation can shift T4-to-T3 conversion. Users on thyroid replacement medication may notice adequacy changes during GH secretagogue cycles.
  5. Component-level interactions. Cross-reference the Sermorelin and Ipamorelin individual peptide pages for full per-component interaction details.

How should Sermorelin + Ipamorelin be stored?

  1. Lyophilized (powder) form: -20°C long-term, 2–8°C short-term (refrigerated). Sermorelin is somewhat less stable than CJC-1295 at room temperature — keep refrigerated consistently.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade Sermorelin or Ipamorelin remains stable — this page does not state a duration as fact.
  3. Reconstitution: bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is not frozen. Freezing damages the peptide structure and renders it inactive.
  5. Sermorelin + Ipamorelin is stored protected from light, in the original container or an amber vial.
  6. Discard if the solution is cloudy, discolored, or contains visible particles.

What are the limitations of Sermorelin + Ipamorelin research?

Most evidence comes from preclinical models and small human studies of each component individually. The combination is widely discussed in the research community but has no controlled trial as a single product. Sermorelin's clinical-use history is the closest regulatory analog for the GHRH-pathway component.

The Sermorelin + Ipamorelin stack is NOT FDA-approved as a combination. Sermorelin was FDA-approved as Geref, but both Geref applications are listed as discontinued in Drugs@FDA, and compounding availability is not an approval; Ipamorelin has no FDA approval. There is no controlled clinical trial of the two-peptide combination as a single product — synergy claims rest on the mechanistic GHRH+GHRP literature and each compound's individual pharmacodynamic data.

Most evidence on combination GH secretagogue stacks is mechanistic and short-term human pharmacodynamic data. Long-term effects of sustained dual-pathway GH-axis stimulation are not fully established — theoretical concerns include insulin resistance, pituitary receptor desensitization, and chronic IGF-1 elevation effects. Standard cycling (8–12 weeks on, 4-week minimum off) is the research-community mitigation strategy.

Research-grade peptide quality varies by source. Sermorelin is less stable than some GHRH analogs and more susceptible to degradation from improper storage or shipping. A third-party HPLC certificate and verified cold-chain handling are the only checks available.

Anti-doping: both sermorelin and ipamorelin are named on the 2026 WADA Prohibited List under S2.2.4 (Growth Hormone Releasing Factors) — sermorelin among the GHRH analogues, ipamorelin among the growth hormone secretagogues. The class is prohibited at all times, and this stack contains both.

Sermorelin + Ipamorelin FAQ

What is the Sermorelin + Ipamorelin stack?

The Sermorelin + Ipamorelin stack is a 2-component growth hormone secretagogue blend: Sermorelin (a GHRH 1-29 analog, the GHRH-pathway partner) + Ipamorelin (a selective GHS-R1a / ghrelin receptor agonist, the pulse trigger). Together they stimulate growth hormone release through two distinct pituitary receptor pathways simultaneously, producing larger and more pulsatile GH output than either compound alone. Both have short half-lives (∼10–20 min for Sermorelin, ∼2 h for Ipamorelin), preserving physiological pulsatile GH release. It's the recommended entry-point stack before stepping up to CJC-1295-based protocols.

Should I start with Sermorelin + Ipamorelin or the GH Stack?

Sermorelin + Ipamorelin is the more commonly reported entry point of the two. Both stacks hit the same dual-pathway mechanism (GHRH receptor + GHS-R1a), and both use short-acting components that preserve pulsatile GH release. The key distinction is regulatory footing: Sermorelin has FDA-recognized clinical history as Geref (both Geref applications are now listed as discontinued in Drugs@FDA; compounded sermorelin is available but is not an FDA-approved product). The GH Stack (CJC-1295 no-DAC + Ipamorelin) uses CJC-1295, which has no published half-life figure for its no-DAC form and no approved clinical analog. Researchers confident with GH secretagogue protocols sometimes move to the GH Stack after establishing tolerability here.

What is Sermorelin's regulatory history?

Sermorelin (GHRH 1-29) was FDA-approved as Geref (sermorelin acetate) for stimulation of GH release in children with GH deficiency and as a GH-axis diagnostic tool. The branded product was withdrawn from the US market in 2002 for business reasons, not safety — it was not pulled due to safety signals. Drugs@FDA lists both Geref applications as discontinued. Compounded sermorelin is available, but compounding availability is not an FDA approval; tesamorelin (Egrifta) is the GHRH analog with a current FDA approval. This is why researchers position Sermorelin + Ipamorelin as the most accessible and beginner-appropriate GH secretagogue stack: the GHRH-pathway component has real-world clinical exposure data. Ipamorelin has no FDA approval and both compounds are prohibited by WADA (Section S2). Research-grade product is sold for laboratory use only.

Why is Ipamorelin the preferred GHRP partner for Sermorelin?

Ipamorelin is selective for the ghrelin / GHS-R1a receptor — it triggers GH release without meaningfully elevating cortisol, ACTH, prolactin, FSH, LH, or TSH. Older GHRPs (GHRP-2, GHRP-6, Hexarelin) produced GH release but also drove cortisol and appetite increases, which undercut the clean GH-axis profile that makes a GHRH+GHRP stack useful. Ipamorelin's selectivity means the combination avoids these side effects, producing a cleaner hormonal response.

When should I take Sermorelin + Ipamorelin?

Pre-bed dosing on an empty stomach is the standard research protocol. Growth hormone naturally pulses during slow-wave sleep, and both Sermorelin and Ipamorelin injected 30–60 minutes before bed reinforce that overnight GH pulse. An empty stomach (at least 2 hours after the last meal) is the most important timing constraint — elevated insulin and somatostatin from a recent meal will blunt the GH response. Some protocols add a second daily dose post-workout.

How does Sermorelin + Ipamorelin compare to CJC-1295 (no DAC) + Ipamorelin?

The main differences are half-life and dosing convenience. Sermorelin has a half-life of ∼10–20 minutes; CJC-1295 no-DAC: no published figure found; CJC-1295 with DAC ∼6–8 days. The DAC form (discussed as a contrast on the CJC-1295 (No DAC) + Ipamorelin (GH Stack) page) only requires 1–2 mg subcutaneously once weekly, making it convenient for researchers who prefer minimal injection frequency. The trade-off is that the long-acting DAC form produces sustained, non-pulsatile GH elevation rather than physiological pulses, and it lacks the regulatory analog that Sermorelin's clinical history provides. The Sermorelin + Ipamorelin stack is the most beginner-friendly and physiologically conservative option; CJC-1295 with DAC is the most convenient once tolerability is established.

How long until results appear?

GH secretagogue stacks build effect over weeks, not days. Sleep quality improvements (deeper slow-wave sleep, better recovery) often appear within 1–2 weeks. Subjective recovery, joint, and connective-tissue changes are sometimes reported to emerge over 4–8 weeks, though no trial or label has been identified establishing this timeframe. Body composition changes (lean mass support, fat distribution) accumulate over 12–24 weeks. Standard research cycles run 8–16 weeks active with a similar off-period to avoid pituitary receptor desensitization.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
  2. Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. https://pubmed.ncbi.nlm.nih.gov/2108187/
  3. Ishida J, Saitoh M, Ebner N, et al. Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development. JCSM Rapid Commun. 2020;3(1):25-37. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
  5. Steiger A, Guldner J, Hemmeter U, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56(2):211-220. https://pubmed.ncbi.nlm.nih.gov/1361964/

Published Studies

The Sermorelin + Ipamorelin combination has no controlled trial as a single product. The studies below are the key peer-reviewed sources for each component and for the dual-pathway mechanistic rationale — the empirical basis for this blend.

European Journal of Endocrinology · 1998Open Access
Ipamorelin, the First Selective Growth Hormone Secretagogue →

Raun K, Hansen BS, Johansen NL, et al.

The landmark selectivity study for Ipamorelin — the GHRP component of this stack. In swine, Ipamorelin did not raise ACTH or cortisol beyond the levels seen after GHRH stimulation, even at more than 200 times the GH ED50, while GHRP-6 and GHRP-2 raised both; none of the secretagogues tested changed prolactin. These are animal data, and the abstract gives no percentage figure. This selectivity is the reason commonly given for pairing Ipamorelin with Sermorelin or CJC-1295.

Journal of Clinical Endocrinology & Metabolism · 1990Paywalled
GH-Releasing Peptide Stimulates GH Release in Normal Men and Acts Synergistically with GH-Releasing Hormone →

Bowers CY, Reynolds GA, Durham D, et al.

Mechanistic study demonstrating supra-additive GH release when a GHRP and native GHRH are co-administered — the scientific foundation for combining a GHRH analog with a GHRP, though this 1990 trial tested a different hexapeptide GHRP and native GHRH(1-44)-NH2 by IV bolus in 18 men, not Sermorelin and Ipamorelin, and not subcutaneously. Submaximal GHRP doses combined with GHRH raised peak serum GH synergistically; the paper reports peak GH concentrations, not an area-under-the-curve figure. The cAMP pathway (GHRHR) and the calcium/PKC pathway (GHS-R1a) converge at the somatotroph, where simultaneous activation is believed to amplify the secretory response beyond what either signal produces alone — the mechanistic rationale for the Sermorelin + Ipamorelin stack, not a direct test of it.

JCSM Rapid Communications · 2020Open Access
Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development →

Ishida J, Saitoh M, Ebner N, et al.

A comprehensive review of the GH secretagogue class providing clinical context for the Sermorelin + Ipamorelin combination. Covers the evolution from native GHRH to stable analogs like Sermorelin (GHRH 1-29), documenting how the dual-pathway approach became the preferred research protocol for GH axis optimization. Also addresses why secretagogue stacks are considered preferable to direct HGH — stimulating endogenous production preserves natural feedback mechanisms and avoids supraphysiological IGF-1 spikes.

Clinical Interventions in Aging · 2006Open Access
Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency →

Walker RF

A clinical review of Sermorelin's mechanism, pharmacology, and historical use as Geref. Documents Sermorelin's FDA-recognized clinical history for GH deficiency diagnostics and pediatric GH deficiency treatment, and its availability through compounding pharmacies for adult use — the regulatory foundation for positioning it as the most accessible GHRH analog. The paper establishes the short half-life (~10–20 minutes), dose-dependent GH stimulation, and the preservation of pituitary feedback regulation that distinguishes Sermorelin from longer-acting GHRH analogs.

Neuroendocrinology · 1992Paywalled
Effects of Growth Hormone-Releasing Hormone and Somatostatin on Sleep EEG and Nocturnal Hormone Secretion in Humans →

Steiger A, Guldner J, Hemmeter U, et al.

Human study establishing the connection between GHRH administration and enhanced slow-wave sleep — the mechanistic basis for pre-bed dosing of GHRH analogs like Sermorelin. GHRH administration increased slow-wave sleep duration and reinforced the natural nocturnal GH pulse. This study underpins the pre-bed dosing protocol used across all GHRH analog research stacks: timing the injection to synchronize with the body's sleep-onset GH surge produces the largest amplitude GH pulse and drives the sleep-quality improvements that are among the earliest subjective effects reported by researchers.

GH AxisGrowth Hormone SecretagogueRecoveryCombination BlendBeginner-Friendly

Related Peptides

SermorelinIpamorelinCJC-1295MK-677

Related Blends

GH Stack (CJC-1295 + Ipamorelin)

We may earn commissions from peptide vendor affiliate links.

Have a question about Sermorelin + Ipamorelin? Send us an email